Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cells of the Innate Immune Response

Cells of the Innate Immune Response

The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

αTIGIT-IL2 achieves tumor regression by promoting tumor-infiltrating regulatory T cell fragility in mouse models.

Nature communications·2025

Same author

Engineering TCR-preserved allogeneic CAR-T cells: leveraging cancer immune evasion principles to establish T-cell tolerance.

Cellular & molecular immunology·2025

Same author

Innate lymphoid cells originate from fetal liver-derived tissue-resident progenitors.

Science immunology·2025

Same author

Author Correction: Targeting myeloid-derived suppressor cells promotes antiparasitic T-cell immunity and enhances the efficacy of PD-1 blockade.

Nature communications·2024

Same author

Targeting myeloid-derived suppressor cells promotes antiparasitic T-cell immunity and enhances the efficacy of PD-1 blockade (15 words).

Nature communications·2024

Same author

The E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling.

Cancer immunology research·2024

Search research articles

Related Experiment Video

Updated: Jun 7, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

CD49a Targeting Enhances NK Cell Function and Antitumor Immunity.

Yu Zhang¹, Yangyang Li², Zhengfeng Zhang¹

¹Biomedical Sciences and Health Laboratory of Anhui Province, Division of Life Sciences and Medicine, Hefei National Research Center for Physical Sciences at the Microscale, School of Basic Medical Sciences, The Institute of Immunology and The CAS Key Laboratory of Innate Immunity and Chronic Disease, University of Science and Technology of China, Hefei, China.

Cancer Immunology Research

|November 21, 2024

Summary

Researchers identified CD49a, a protein on Natural Killer (NK) cells, as a promising target for cancer immunotherapy. Blocking CD49a on NK cells can enhance anti-tumor responses and overcome treatment resistance.

More Related Videos

Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells

Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells

Published on: February 22, 2020

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

Related Experiment Videos

Last Updated: Jun 7, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells

Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells

Published on: February 22, 2020

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

Area of Science:

Immunology
Cancer Biology
Cellular and Molecular Immunology

Background:

Immune checkpoint blockade (ICB) therapies are limited by ~70% treatment resistance.
Novel immunotherapeutic targets are crucial for improving cancer treatment efficacy.
CD49a is a membrane protein found on Natural Killer (NK) and T cells.

Purpose of the Study:

To investigate the role of CD49a on tumor-infiltrating NK cells in cancer.
To evaluate CD49a as a potential immunotherapeutic target for enhancing anti-tumor immunity.

Main Methods:

Analysis of CD49a expression on tumor-infiltrating NK cells in mouse models.
Assessment of NK cell exhaustion markers in CD49a+ versus CD49a- populations.
Evaluation of tumor growth and survival in mice with CD49a deficiency or CD49a blockade.
Combination therapy studies with anti-PD-L1.

Main Results:

CD49a was highly expressed on tumor-infiltrating NK cells across various mouse tumor models.
CD49a+ NK cells exhibited increased exhaustion compared to CD49a- NK cells.
Genetic deletion or antibody blockade of CD49a suppressed tumor growth and improved survival.
Combination therapy of CD49a blockade with anti-PD-L1 demonstrated enhanced anti-tumor efficacy.

Conclusions:

CD49a expressed on NK cells represents a viable immunotherapeutic target.
Targeting CD49a holds potential for overcoming ICB resistance and improving cancer treatment outcomes.
CD49a-targeted therapies may offer a novel strategy for enhancing anti-tumor immunity.